Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4468-4476
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4468
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4468
Group | D0 | D14 | D14 - D0 |
Control group | 20.22 ± 0.01 | 18.15 ± 0.03a | 2.07 ± 0.03 |
Low-dose group of ISAP | 20.47 ± 0.71 | 18.89 ± 0.34a | 1.58 ± 0.83 |
Medium-dose group of ISAP | 20.28 ± 0.02 | 19.08 ± 0.34a | 1.20 ± 0.34 |
High-dose group of ISAP | 20.39 ± 0.05 | 19.51 ± 0.59a,b,c | 0.87 ± 0.07 |
Capecitabine group | 20.46 ± 0.01 | 16.29 ± 0.08a | 4.18 ± 0.06 |
- Citation: Wang W, Wang J, Ren XX, Yue HL, Li Z. Effects of invigorating-spleen and anticancer prescription on extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway in colon cancer mice model. World J Gastrointest Oncol 2024; 16(11): 4468-4476
- URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4468.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4468